Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Pykus Therapeutics is raising $2,487,307.00 in new funding. Sources indicate as part of senior management President, Tony Stefater played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pykus Therapeutics

Pykus Therapeutics Inc. is a clinical stage medical technology company developing biodegradable polymers to provide solutions for unmet needs in vitreoretinal surgery. Pykus was founded in 2016 and is led by a team of committed physicians, scientists, engineers, and entrepreneurs. Our lead product, PYK-1105, is a novel biodegradable hydrogel that allows patients to recover from retina surgery faster and more comfortably. PYK-1105 is Pykus Therapeutics’ lead product. It is a novel, in situ cross linking, biodegradable hydrogel. PYK-1105 is administered in the operating room and is designed to allow the retina to heal without requiring facedown positioning, blurred vision, prohibition on air travel, or a need for repeat surgery.

To learn more about Pykus Therapeutics, visit http://pykustherapeutics.com/

Contact:
Tony Stefater, President
617-394-8960

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved